Last reviewed: 5/26 · Verify current state guidance before relying on any specific claim
Michigan has the clearest constitutional framework for stem cell research of any U.S. state. In November 2008, Michigan voters approved Proposal 08-2, amending the state constitution to authorize embryonic stem cell research using donated embryos from fertility clinics — reversing earlier statutory prohibitions.
The amendment imposed specific limits (a 14-day cap on embryo use, prohibition on the purchase or sale of embryos) and required that all stem cell research and therapies comply with general state and local laws of general applicability. Michigan was also one of the earliest states to adopt a Right to Try law, in 2014. The Michigan Board of Medicine regulates physicians under the Public Health Code; there is no Michigan-specific commercial stem cell statute beyond the constitutional framework for embryonic research.
For the federal framework that applies in every state — FDA regulation of cell and tissue products under 21 CFR Part 1271, the 361/351 distinction, FDA enforcement history, and the federal Right to Try Act — see How Regenerative Medicine Is Regulated in the United States.
Michigan’s Constitutional Framework
Michigan Constitution Article I, Section 27 (“Human embryo and embryonic stem cell research”) was added by ballot Proposal 08-2 in 2008. The full text is available at the Michigan Legislature website (MCL — Article I § 27).
The amendment authorizes scientific and medical research, including embryonic stem cell research, subject to several explicit conditions:
- Embryos used for research must be donated from in vitro fertilization treatments and would otherwise be discarded; embryos may not be created for research purposes.
- Embryos may not be used after 14 days post-cell-division (excluding frozen storage time).
- No person may sell or purchase embryos for stem cell research, therapies, or cures for valuable consideration.
- All research and therapies must comply with state and local laws of general applicability, including those concerning scientific and medical practice, patient safety, and privacy.
The amendment is the operative legal framework for embryonic stem cell work in Michigan. It does not directly regulate adult or autologous stem cell therapy, which falls under federal FDA rules and Michigan’s general medical practice statutes.
Michigan also maintains a state cord blood stem cell bank network supporting research and therapy development; see the Michigan Department of Health and Human Services Cord Blood Stem Cell Bank Program.
The Michigan Board of Medicine
The Michigan Board of Medicine, within the Department of Licensing and Regulatory Affairs (LARA), Bureau of Professional Licensing, licenses and regulates allopathic physicians. The Michigan Board of Osteopathic Medicine and Surgery regulates osteopathic physicians separately.
Board authority is set out in the Michigan Public Health Code, Article 15, Part 170 (Medicine). As of late 2025 [VERIFY current Board publications], the Board has not issued comprehensive guidance specific to commercial stem cell, PRP, NAD+, or peptide therapy. Standard practice-of-medicine rules apply.
Michigan’s Right to Try Law
Michigan was one of the earliest states to adopt a Right to Try statute: Public Act 345 of 2014 (and companion Public Act 346 of 2014), effective October 17, 2014. The Act is codified at MCL 333.26451–333.26457.
The Michigan law authorizes eligible patients with an “advanced illness” — defined as a progressive disease or medical or surgical condition that entails significant functional impairment, not considered by the treating physician to be reversible even with current FDA-approved treatments — to request an investigational drug, biological product, or device that has successfully completed FDA Phase 1 clinical trials. The Act includes provider protections, preventing state authorities from disciplining providers who offer eligible patients access to investigational treatments under the Act.
The Michigan law operates in parallel with the federal Right to Try Act of 2018. It does not authorize clinics to offer unapproved stem cell, exosome, or peptide therapies outside the narrow conditions of the Act — advanced illness, exhausted FDA-approved options, physician recommendation, access through the actual sponsor of an investigational product.
The full Act text: Right to Try Act — Public Act 345 of 2014 (PDF).
IV Therapy and NAD+ in Michigan
NAD+ intravenous therapy is broadly available in Michigan. Registered nurses may administer IV therapy under physician orders; nurse practitioners have broad scope of practice in Michigan including independent prescribing authority. IV lounges, mobile IV providers, and concierge services operate openly in Detroit, Grand Rapids, Lansing, Ann Arbor, and other metros.
NAD+ itself is compounded through 503A or 503B pharmacies and is not FDA-approved for any indication. Patients pay out of pocket.
Telemedicine and Out-of-State Providers
Michigan is a member of the Interstate Medical Licensure Compact. Michigan residents can establish telehealth relationships with out-of-state physicians licensed through the compact.
Michigan also maintains its own telemedicine rules within the Public Health Code, generally permitting physicians to establish patient relationships via telehealth subject to standard-of-care and informed-consent requirements.
Notable Enforcement
The FDA’s public Warning Letter database is the authoritative source for federal enforcement against specific Michigan-based clinics [VERIFY against current list]. The 2021 federal injunction in United States v. US Stem Cell Clinic, LLC applies in Michigan as in every state.
Michigan has not been a notable focus of state attorney general action against the broader regenerative medicine sector.
Cost and Clinic Landscape
Regenerative medicine clinics in Michigan cluster in the Detroit, Grand Rapids, Lansing, Ann Arbor, Kalamazoo, and Flint metros. Celmedica currently lists [X] verified clinics across Michigan — pull live count.
Typical out-of-pocket pricing in Michigan (representative ranges; individual clinics vary):
- PRP joint injection: $500 – $1,200 per session
- Autologous stem cell injection (single joint or area): $4,500 – $9,000
- NAD+ IV (single drip): $400 – $800
- Peptide protocols: $200 – $1,200 per month, varies by compound
Insurance generally does not cover regenerative therapies. Some orthopedic indications for PRP are occasionally covered.
The University of Michigan, Wayne State University, and Michigan State University all operate research-active medical centers; legitimate clinical-trial access for investigational protocols is sometimes available through clinicaltrials.gov.
Frequently Asked Questions
Is stem cell therapy legal in Michigan? Michigan has no statute prohibiting adult or autologous stem cell therapy. Embryonic stem cell research is constitutionally authorized under Article I, Section 27, with specific limits. Commercial stem cell practice operates under federal FDA rules and Michigan Board of Medicine practice standards.
What does Michigan’s constitutional amendment on stem cell research say? Article I, Section 27 of the Michigan Constitution (adopted 2008) authorizes embryonic stem cell research using donated embryos from in vitro fertilization that would otherwise be discarded, subject to a 14-day post-cell-division limit and a prohibition on buying or selling embryos.
Does Michigan’s Right to Try Act cover stem cell therapy? Only in the narrow case of investigational stem cell products that have completed FDA Phase 1 trials, for a patient with an advanced illness, accessed through the actual product sponsor. The Act does not authorize clinics to offer unapproved stem cell therapy as a routine cash-pay service.
Can I get NAD+ IV therapy in Michigan? Yes. NAD+ IV is broadly available through clinics, IV lounges, mobile services, and nurse-practitioner-led IV therapy practices. The therapy is compounded and not FDA-approved for any indication.
How much does stem cell therapy cost in Michigan? Autologous stem cell injections for a single joint typically range $4,500–$9,000 in Michigan metros. PRP runs $500–$1,200. Clinical-trial participation at the University of Michigan, Wayne State, or Michigan State medical centers is sometimes meaningfully cheaper or free.
Bottom Line
Michigan combines an unusually clear constitutional research framework with one of the country’s earliest Right to Try laws. The state’s posture toward legitimate regenerative research is supportive; the commercial clinic sector operates primarily under federal FDA rules and Michigan Board of Medicine practice standards. Patients should focus on physician credentials, FDA product classification of the specific therapy, and whether clinical-trial access is available at a Michigan academic medical center before pursuing cash-pay options.
Next steps:
- Browse verified regenerative medicine clinics in Michigan →
- Read our guides to stem cell therapy, PRP, and NAD+ IV therapy
- Search clinicaltrials.gov for active trials at University of Michigan, Wayne State, and Michigan State medical centers
- If clinical access is limited or cost-prohibitive: see our review of consumer-grade stem cell mobilizer supplements
[FTC affiliate disclosure block]: Some links in this guide may earn Celmedica a commission at no additional cost to you. Read our affiliate disclosure.
[Medical disclaimer]: This guide is for informational purposes and does not constitute legal or medical advice. State laws and regulatory guidance change. Verify current rules with the Michigan Board of Medicine, LARA, and the FDA, and consult a qualified physician before pursuing any therapy.
References
For the federal regulatory citations, see the federal baseline references.
Michigan-specific:
- Michigan Constitution Article I § 27 — Human Embryo and Embryonic Stem Cell Research
- Right to Try Act — Public Act 345 of 2014 (PDF)
- MCL 333.26451 — Right to Try Act, Definitions
- MCL 333.26453 — Right to Try Act, Manufacturer Provisions
- Michigan Board of Medicine — LARA
- Interstate Medical Licensure Compact
- FDA Warning Letter database